Contribute Try STAT+ Today

Extraordinary times call for extraordinary financing instruments, according to one California venture capital firm.

A San Francisco-based early-stage investor, Fifty Years, has offered $25,000 apiece to 14 of the health tech companies it’s already invested in, all of which are now working on coronavirus-related projects — and that money is coming with far fewer strings than usual. It’s hoping the extra money will allow its portfolio companies to produce tests, treatments, or basic needed supplies like masks or hand sanitizers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.